CytoMed Therapeutics Limited (GDTC) Balance Sheet
GDTC balance sheet, 2025
December 31, 2025 · Singapore dollarsS$8.0M assets = S$1.1M liabilities + S$6.9M equity
Both columns are drawn to the same scale: what GDTC owns equals what it owes plus shareholders’ equity. Hover a block for its value.
GDTC financial health
Descriptive bands, not a rating. Fiscal 2025.
GDTC balance sheet trends, 2019–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | S$2.9M2019 | S$8.0M2025 | +18.1%/yr | |
| Total liabilities | S$1.0M2019 | S$1.1M2025 | +1.9%/yr | |
| Shareholders’ equity | S$1.9M2019 | S$6.5M2025 | +22.5%/yr | |
| Cash & short-term investments | S$459,2222019 | S$2.1M2025 | +28.8%/yr | |
| Total debt | S$674,6092019 | S$482,5622025 | −5.4%/yr | |
| Net cash (debt) | −S$215,3872019 | S$1.6M2025 | +S$1.8M | |
| Working capital | S$172,3662019 | S$3.0M2025 | +S$2.8M | |
| Current ratio | 1.462019 | 5.172025 | +3.71 | |
| Debt / equity | 0.352019 | 0.072025 | −0.27 | |
| Shares outstanding | 5.6M2019 | 11.6M2025 | +13.1%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
GDTC assets
GDTC liabilities and equity
GDTC debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
GDTC balance sheet in Singapore dollars
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Assets | |||||||
| Cash & short-term investments | S$2.1M | S$5.0M | S$9.0M | S$1.6M | S$2.5M | S$930,810 | S$459,222 |
| Cash & equivalents | S$2.1M | S$5.0M | S$9.0M | S$1.6M | S$2.5M | S$887,223 | S$374,424 |
| Short-term investments | — | S$200,351 | S$47,190 | S$11,560 | S$15,267 | S$43,586 | S$84,798 |
| Receivables | S$103,859 | S$18,777 | S$204,748 | S$54,536 | S$15,222 | S$229,571 | S$1 |
| Inventory | S$1.1M | S$838,640 | S$680,586 | S$578,854 | S$432,590 | S$240,971 | S$48,116 |
| Other current assets | S$396,125 | S$172,692 | S$219,246 | S$285,008 | S$307,694 | S$70,912 | S$41,675 |
| Total current assets | S$3.7M | S$6.0M | S$10.1M | S$2.5M | S$3.3M | S$1.5M | S$549,014 |
| Property, plant & equipment (net) | S$3.7M | S$3.3M | S$2.1M | S$2.5M | S$2.5M | S$2.3M | S$2.4M |
| Goodwill & intangible assets | S$124,894 | S$93,029 | S$12,446 | S$18,895 | S$32,096 | S$45,347 | S$36,358 |
| Long-term investments | S$18,210 | S$220,950 | S$195,073 | S$239,424 | S$272,970 | S$0 | S$0 |
| Other non-current assets | S$487,282 | S$499,844 | S$538 | S$1,118 | S$640 | S$2 | S$3 |
| Total assets | S$8.0M | S$10.1M | S$12.4M | S$5.3M | S$6.1M | S$3.8M | S$2.9M |
| Liabilities | |||||||
| Accounts payable | S$124,742 | S$38,623 | S$24,684 | S$14,695 | S$46,356 | S$18,956 | S$12,454 |
| Short-term debt | S$60,445 | S$45,900 | S$40,359 | S$3.8M | S$2.7M | S$2.4M | S$43,598 |
| Deferred revenue | S$182,807 | S$109,150 | S$8,400 | S$2,603 | S$21,972 | S$23,034 | — |
| Total current liabilities | S$709,169 | S$606,487 | S$718,905 | S$4.2M | S$2.9M | S$2.7M | S$376,648 |
| Long-term debt | S$368,656 | S$394,310 | S$407,772 | S$468,827 | S$539,119 | S$590,674 | S$0 |
| Lease obligations | S$73,059 | S$31,290 | S$6,324 | S$14,419 | S$23,131 | S$31,122 | — |
| Other long-term liabilities | S$53,461 | S$22,936 | S$1,117 | S$8,921 | S$16,614 | S$24,891 | S$631,013 |
| Total liabilities | S$1.1M | S$1.0M | S$1.1M | S$4.7M | S$3.5M | S$3.3M | S$1.0M |
| Shareholders' equity | |||||||
| Common stock & paid-in capital | S$24.7M | S$23.8M | S$23.8M | S$9.0M | S$6.6M | S$3.5M | S$3.0M |
| Retained earnings (deficit) | −S$18.8M | −S$14.8M | −S$12.4M | −S$8.2M | −S$5.1M | −S$3.0M | −S$1.1M |
| Accumulated other comprehensive income | S$604,904 | S$20,220 | −S$143,863 | −S$128,076 | S$1.1M | −S$8,369 | −S$1,751 |
| Minority interest | S$309,221 | S$77,749 | −S$956 | −S$682 | — | — | — |
| Total shareholders' equity | S$6.5M | S$9.0M | S$11.3M | S$589,712 | S$2.6M | S$477,015 | S$1.9M |
| Key figures | |||||||
| Total debt | S$482,562 | S$463,147 | S$449,247 | S$4.2M | S$3.3M | S$3.0M | S$674,609 |
| Net cash (debt) | S$1.6M | S$4.5M | S$8.6M | −S$2.7M | −S$732,405 | −S$2.1M | −S$215,387 |
| Working capital | S$3.0M | S$5.4M | S$9.4M | −S$1.7M | S$346,065 | −S$1.3M | S$172,366 |
| Tangible book value | S$6.4M | S$8.9M | S$11.3M | S$570,817 | S$2.6M | S$431,668 | S$1.9M |
| Shares outstanding | 11.6M | 11.5M | 10.6M | 7.9M | 6.9M | 5.9M | 5.6M |
| Current ratio | 5.17 | 9.89 | 14.08 | 0.60 | 1.12 | 0.54 | 1.46 |
| Quick ratio | 3.10 | 8.22 | 12.83 | 0.39 | 0.87 | 0.42 | 1.22 |
| Debt / equity | 0.07 | 0.05 | 0.04 | 7.19 | 1.26 | 6.26 | 0.35 |
| Equity / assets | 82.0% | 89.1% | 90.9% | 11.2% | 42.6% | 12.5% | 65.8% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | S$1.5M | S$1.5M | S$2.1M | S$2.1M | S$2.9M | S$2.9M | S$5.0M | S$5.0M | S$6.8M | S$6.8M | S$9.0M | S$9.0M |
| Cash & equivalents | S$1.5M | S$1.5M | S$2.1M | S$2.1M | S$2.9M | S$2.9M | S$5.0M | S$5.0M | S$6.5M | S$6.5M | S$9.0M | S$9.0M |
| Short-term investments | — | — | — | — | — | S$200,351 | — | — | S$351,053 | S$352,144 | — | — |
| Receivables | S$414,076 | S$49,629 | S$103,859 | S$103,859 | S$1.2M | S$1.2M | S$18,782 | S$19,065 | S$295,192 | S$204,748 | S$204,748 | S$1 |
| Inventory | S$0 | S$1.0M | S$1.1M | S$1.1M | S$0 | S$838,640 | S$0 | S$851,492 | S$718,540 | S$720,773 | −S$204,747 | S$679,953 |
| Other current assets | S$1.4M | S$684,333 | S$396,125 | S$396,125 | S$2 | S$0 | S$1.0M | S$175,340 | S$0 | S$0 | S$1.1M | S$423,599 |
| Total current assets | S$3.2M | S$3.2M | S$3.7M | S$3.7M | S$4.1M | S$4.1M | S$6.0M | S$6.1M | S$7.7M | S$7.7M | S$10.1M | S$10.1M |
| Property, plant & equipment (net) | S$3.6M | S$3.6M | S$3.7M | S$3.7M | S$3.5M | S$3.5M | S$3.3M | S$3.3M | S$2.5M | S$2.5M | S$2.1M | S$2.1M |
| Goodwill & intangible assets | S$104,309 | S$104,396 | S$124,894 | S$124,894 | S$72,818 | S$73,080 | S$93,050 | S$94,454 | S$11,006 | S$11,040 | S$12,413 | S$12,435 |
| Long-term investments | S$0 | S$0 | S$18,210 | S$0 | S$0 | S$0 | S$220,950 | S$0 | S$211,013 | S$0 | S$195,073 | S$0 |
| Other non-current assets | S$25,745 | S$25,763 | S$487,282 | S$505,492 | S$731,209 | S$729,907 | S$500,000 | S$731,839 | S$499,666 | S$712,887 | S$0 | S$195,427 |
| Total assets | S$7.0M | S$7.0M | S$8.0M | S$8.0M | S$8.4M | S$8.4M | S$10.1M | S$10.2M | S$10.9M | S$10.9M | S$12.4M | S$12.4M |
| Liabilities | ||||||||||||
| Accounts payable | S$25,058 | S$25,079 | S$124,742 | S$124,742 | S$479,425 | S$478,805 | S$38,633 | S$39,216 | S$44,811 | S$44,951 | S$24,618 | S$24,661 |
| Short-term debt | S$62,366 | S$62,419 | S$60,445 | S$60,445 | S$58,043 | S$57,968 | — | S$46,603 | S$37,368 | S$37,485 | S$40,250 | S$40,320 |
| Deferred revenue | S$108,125 | — | S$182,807 | — | — | S$109,150 | — | — | S$7,065 | S$4,136 | S$8,400 | — |
| Total current liabilities | S$1.2M | S$1.2M | S$709,169 | S$709,169 | S$705,646 | S$704,734 | S$606,622 | S$615,782 | S$357,749 | S$358,859 | S$716,943 | S$718,236 |
| Long-term debt | S$0 | S$0 | S$368,656 | S$0 | S$0 | S$0 | S$394,310 | S$0 | S$390,896 | S$0 | S$407,772 | S$0 |
| Lease obligations | — | — | S$73,059 | — | — | — | S$31,290 | — | S$2,565 | — | S$6,324 | — |
| Other long-term liabilities | S$391,393 | S$391,715 | S$53,461 | S$422,117 | S$433,337 | S$432,777 | S$23,028 | S$423,640 | S$0 | S$391,925 | S$0 | S$408,508 |
| Total liabilities | S$1.6M | S$1.6M | S$1.1M | S$1.1M | S$1.1M | S$1.1M | S$1.0M | S$1.0M | S$748,459 | S$750,785 | S$1.1M | S$1.1M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | S$24.8M | S$24.8M | S$24.7M | S$24.7M | S$23.9M | S$23.8M | — | S$24.2M | S$23.8M | S$23.9M | S$23.7M | S$23.8M |
| Retained earnings (deficit) | −S$20.6M | −S$20.6M | −S$18.8M | −S$18.8M | −S$17.2M | −S$17.1M | −S$14.8M | −S$15.1M | −S$13.4M | −S$13.5M | −S$12.3M | −S$12.4M |
| Accumulated other comprehensive income | S$779,922 | S$780,563 | S$604,904 | S$716,129 | S$446,084 | S$445,507 | — | S$20,529 | −S$211,907 | −S$212,565 | −S$217,402 | −S$143,729 |
| Minority interest | — | — | S$309,221 | — | — | — | S$77,749 | — | — | — | — | — |
| Total shareholders' equity | S$5.0M | S$5.0M | S$6.5M | S$6.5M | S$7.2M | S$7.2M | S$9.0M | S$9.1M | S$10.2M | S$10.2M | S$11.2M | S$11.3M |
| Key figures | ||||||||||||
| Total debt | S$453,760 | S$454,134 | S$482,562 | S$482,562 | S$491,381 | S$490,746 | S$394,310 | S$470,244 | S$428,082 | S$429,410 | S$448,022 | S$448,829 |
| Net cash (debt) | S$1.0M | S$1.0M | S$1.6M | S$1.6M | S$2.4M | S$2.4M | S$4.6M | S$4.6M | S$6.4M | S$6.4M | S$8.5M | S$8.6M |
| Working capital | S$2.0M | S$2.0M | S$3.0M | S$3.0M | S$3.4M | S$3.4M | S$5.4M | S$5.5M | S$7.3M | S$7.4M | S$9.4M | S$9.4M |
| Tangible book value | S$4.9M | S$4.9M | S$6.4M | S$6.4M | S$7.1M | S$7.1M | S$8.9M | S$9.0M | S$10.1M | S$10.2M | S$11.2M | S$11.3M |
| Shares outstanding | 11.9M | 11.9M | 11.8M | 11.8M | 11.8M | 11.8M | 11.5M | 11.5M | 11.5M | 11.5M | 11.5M | 11.5M |
| Current ratio | 2.64 | 2.64 | 5.17 | 5.17 | 5.81 | 5.81 | 9.89 | 9.89 | 21.53 | 21.53 | 14.08 | 14.08 |
| Quick ratio | 1.53 | 1.23 | 3.10 | 3.10 | 5.81 | 5.81 | 8.22 | 8.22 | 19.89 | 19.63 | 12.83 | 12.55 |
| Debt / equity | 0.09 | 0.09 | 0.07 | 0.07 | 0.07 | 0.07 | 0.04 | 0.05 | 0.04 | 0.04 | 0.04 | 0.04 |
| Equity / assets | 70.9% | 70.9% | 82.0% | 82.0% | 85.5% | 85.5% | 89.1% | 89.1% | 93.1% | 93.1% | 90.9% | 90.9% |
Quarterly columns are labeled by the month the quarter ended. Figures in Singapore dollars as reported (latest annual report filed March 31, 2026); data from EODHD.
GDTC financial position
At the end of fiscal 2025 (December 31, 2025), CytoMed Therapeutics had total assets of S$8.0 million (down 20.7% from a year earlier), total liabilities of S$1.1 million and shareholders' equity of S$6.5 million. It held S$2.1 million in cash and short-term investments against S$0.5 million of debt, a net cash position of S$1.6 million. Its current ratio was 5.17. In the latest quarter (ended June 30, 2026) total assets were S$7.0 million and equity S$5.0 million.
Related: GDTC income statement, GDTC cash flow statement, GDTC key metrics. See the GDTC stock overview for the latest quote and news.
GDTC balance sheet FAQ
What are CytoMed Therapeutics's total assets?
CytoMed Therapeutics reported total assets of S$8.0 million at the end of fiscal 2025 (December 31, 2025), compared with S$10.1 million a year earlier.
How much debt does CytoMed Therapeutics have?
CytoMed Therapeutics had S$0.5 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.07.
How much cash does CytoMed Therapeutics have?
CytoMed Therapeutics held S$2.1 million in cash and short-term investments at the end of fiscal 2025; with S$0.5 million of debt that is net cash of S$1.6 million.
What is CytoMed Therapeutics's book value?
CytoMed Therapeutics's shareholders' equity (book value) was S$6.5 million at the end of fiscal 2025.
What is CytoMed Therapeutics's current ratio?
CytoMed Therapeutics had current assets of S$3.7 million and current liabilities of S$0.7 million, a current ratio of 5.17 (it can cover its short-term obligations).
How much goodwill does CytoMed Therapeutics have?
CytoMed Therapeutics carried S$0.1 million of goodwill and intangible assets, 1.6% of total assets, at the end of fiscal 2025.